Influence of titration of antiseizure medications on treatment selection: Results of an online survey with clinicians in the United States
Autor: | Matthew Holtzman, Craig Plauschinat, Betsy Williams, John Baker, Barry E. Gidal, Nicole Sparling, Joshua Maher, Trevor Resnick |
---|---|
Rok vydání: | 2020 |
Předmět: |
medicine.medical_specialty
business.industry Attitude of Health Personnel Health Personnel United States 03 medical and health sciences Behavioral Neuroscience 0302 clinical medicine Key factors Convulsive Seizures Neurology Surveys and Questionnaires Emergency medicine medicine Humans Titration 030212 general & internal medicine Neurology (clinical) business Healthcare providers 030217 neurology & neurosurgery |
Zdroj: | Epilepsybehavior : EB. 117 |
ISSN: | 1525-5069 |
Popis: | Introduction Most antiseizure medications (ASM) need to be titrated before the optimal dose is achieved. Titration can last several weeks to months. We assessed the impact titration schedules have on ASM treatment-related decisions in the United States (US). Methods An online survey was conducted with different healthcare providers (HCPs) in the US involved in the treatment and management of patients with epilepsy. The survey contained three sections: the first section with screening questions; the second on key factors that influence a HCP’s decision-making when selecting treatments for different types of seizures and different treatment lines; and the third on the HCP’s knowledge and perceptions regarding ASM titration for the treatment of patients with epilepsy. Results One-hundred and fifty HCPs (63% neurologists) completed the survey. Most HCPs considered titration schedule to be important, with only 1–3% of HCPs, depending on type of seizure, considering the titration schedule to be “not important at all” when prescribing therapy. Healthcare providers’ acceptance of titration increased with shorter durations (≥50% accepted titration periods of ≤2 weeks), and lower number of tablets/capsules per dose (≥50% accepted ≤3 tablets/capsules per dose), doses (≥50% accepted ≤2 doses/day), and steps (≥50% accepted ≤3 steps/dose change). Most HCPs (68–91% depending on type of seizure) considered a titration duration of 6 or more weeks only somewhat acceptable or somewhat or highly unacceptable. Almost all HCPs selected “somewhat familiar”, “familiar”, or “very familiar” as the attribute that best defines their knowledge level of titration, with only 4% selecting “a little familiar”. While 87% of HCPs agreed or strongly agreed that they could easily understand titration schedules, only 27% of them agreed or strongly agreed that patients could easily understand titration schedules and 58% of HCPs considered that adhering to the titration schedule was difficult for patients. Most HCPs agreed or strongly agreed that a complex or long titration schedule renders it difficult to achieve their treatment objectives. Conclusions Healthcare providers take into account the duration and complexity of the titration period in their ASM prescribing decision-making and prefer shorter and simpler titration schedules, particularly for patients who are experiencing convulsive seizures and starting monotherapy. There was a clear difference between the HCP’s belief in their own ability to understand a titration schedule, and their belief that the patient would be able to follow the titration schedule appropriately |
Databáze: | OpenAIRE |
Externí odkaz: |